Giant Pharmacy 363 is an authorized DME supplier for medicare equipments and products.
Giant Pharmacy 363 is a Community/Retail Pharmacy in Dundalk, Maryland. This pharmacy is owned and operated by Giant Of Maryland Llc. It is located at 1400 Merritt Blvd, Dundalk and it's customer support contact number is 410-631-1280. The authorized person of Giant Pharmacy 363 is Brad Dayton who is Director of the pharmacy and his contact number is 617-770-8782. Active license number of Giant Pharmacy 363 is PO2617 for Community/Retail Pharmacy in Maryland. Giant Pharmacy 363 accepts medicare which means medicare covered patients will not be billed for any more than the Medicare deductible and coinsurance. Giant Pharmacy 363 is a pharmacy where pharmacists store, prepare, and dispense medicinal preparations and/or prescriptions for a local patient population in accordance with federal and state law; counsel patients and caregivers (sometimes independent of the dispensing process); administer vaccinations; and provide other professional services associated with pharmaceutical care such as health screenings, consultative services with other health care providers, collaborative practice, disease state management, and education classes.
Pharmacy Details:
Giant Pharmacy 363 type, location, contact phone number and fax are as below. Patients can directly walkin to the pharmacy or can call on the below given customer support phone number for enquiries.
Name:
Giant Pharmacy 363
Type:
Community/Retail Pharmacy
Location:
1400 Merritt Blvd, Dundalk, Maryland, 21222-2110
Phone:
410-631-1280
Fax:
410-631-1288
Authorized/Official Person Profile:
Officially authorized person to contact for any management issues or complaints of this pharmacy is as below. Person's position and contact details are also mentioned below.
Name:
Brad Dayton
Position:
Director
Contact Number:
617-770-8782
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of given pharmacy are as mentioned below.
NPI Number:
1487687737
NPI Enumeration Date:
09 Jul, 2006
NPI Last Update On:
17 Nov, 2011
Medical Licenses:
Organizations can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Giant Pharmacy 363 are as mentioned below.
Specialization
License Number
State
Status
Community/Retail Pharmacy
PO2617
Maryland
Primary
Durable Medical Equipment & Medical Supplies
PO2617
Maryland
Secondary
Pharmacy
PO2617
Maryland
Secondary
Other Medical Identifiers:
Other legacy medical identifiers of the pharmacy such as Medicaid, Medicare PIN, NSC, UPIN etc. are mentioned as below.
Identifier
Type
State
Issuer
2125967
Other
Other Id Number-commercial Number
699615900
Medicaid
Maryland
Medicare Enrollment:
Giant Pharmacy 363 is enrolled in medicare and it's Pac Id, enrollment Id, registered name and type is as stated below.
PAC ID:
Enrollment ID:
Org Name
Medicare Entity Type
7113914219
O20100930054019
Giant Of Maryland Llc
DME SUPPLIER - PHARMACY
Products Available:
Giant Pharmacy 363 has following products available for sale under medicare.
Products
Blood Glucose Monitors & Supplies: Non-mail Order
Canes & Crutches
Commodes, Urinals, & Bedpans
Diabetic Shoes & Inserts: Prefabricated
Enteral Equipment And/or Supplies
Enteral Nutrients
Heat & Cold Applications
Ostomy Supplies
Parenteral Equipment And/or Supplies
Surgical Dressings
Walkers
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1400 Merritt Blvd, Dundalk, Maryland
Zip:
21222-2110
Phone Number:
--
Fax Number:
--
Patients can reach Giant Pharmacy 363 at 1400 Merritt Blvd, Dundalk, Maryland or can call on customer care at 410-631-1280.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.